N,N,N-Trimethyl-6-(2-propenylamino)-1-hexanaminium, chloride | 182815-42-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N,N,N-Trimethyl-6-(2-propenylamino)-1-hexanaminium, chloride
• 英文别名: trimethyl-[6-(prop-2-enylamino)hexyl]azanium;chloride
• CAS: 182815-42-5
• 化学式: C12H27ClN2
• 分子量: 234.81
• InChiKey: RISCULYDRMPQKP-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -0.97
• 重原子数：
  15
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF GASTROINTESTINAL INFECTIONS
  申请人：Lumena Pharmaceuticals, Inc.

  公开号：US20150119345A1

  公开（公告）日：2015-04-30

  Provided herein are methods for treating or preventing gastrointestinal and/or liver infections utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents and/or FXR agonists. Also provided herein are methods for increasing the levels of an enteroendocrine peptide or hormone in an individual suffering from a gastrointestinal infection or liver infection utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents and/or FXR agonists.

  本文提供了利用胆汁酸转运抑制剂和/或肠内分泌肽增强剂和/或FXR激动剂治疗或预防胃肠和/或肝感染的方法。本文还提供了利用胆汁酸转运抑制剂和/或肠内分泌肽增强剂和/或FXR激动剂增加患有胃肠感染或肝感染的个体体内肠内分泌肽或激素水平的方法。
• Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease
  申请人：Lumena Pharmaceuticals, Inc.

  公开号：US20130108573A1

  公开（公告）日：2013-05-02

  Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.

  本文提供了一种治疗或改善高胆固醇血症或胆汁淤积性肝病的方法，即通过向需要的个体施用治疗有效量的顶端钠依赖性胆酸转运蛋白抑制剂（ASBTI）或其药用可接受盐。还提供了一种治疗或改善肝病、降低血清胆酸或肝内胆酸水平、治疗或改善瘙痒、降低肝酶或减少胆红素的方法，即通过向需要的个体施用治疗有效量的ASBTI或其药用可接受盐。
• Orlistat compositions
  申请人：——

  公开号：US20020035089A1

  公开（公告）日：2002-03-21

  A pharmaceutical combination or composition containing a lipase inhibitor, preferably orlistat, and a bile acid sequestrant is useful for treating obesity.

  一种含有脂肪酶抑制剂（最好是奥利司他）和胆酸螯合剂的药物组合或配方对治疗肥胖有效。
• Crosslinked Polymers
  申请人：Sathe Dhananjay Govind

  公开号：US20110159087A1

  公开（公告）日：2011-06-30

  Disclosed herein are pharmaceutical compositions comprising wet granulated bile acid sequestrants having the general Formula I shown, and their process of preparation. The present invention also discloses process for preparation of Colesevelam hydrochloride, an antilipemic agent.

  本发明涉及一种制备方法的湿法制粒胆汁酸结合剂的药物组合物，其具有所示的一般式I，以及它们的制备过程。本发明还揭示了一种制备抗脂质血症药物Colesevelam hydrochloride的方法。
• Bile Acid Recycling Inhibitors for Treatment of Pancreatitis
  申请人：GEDULIN Bronislava

  公开号：US20130034536A1

  公开（公告）日：2013-02-07

  Provided herein are methods and compositions comprising bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents and/or FXR agonists for the treatment of pancreatitis or prevention of pancreatitis.

  本文提供了一种治疗胰腺炎或预防胰腺炎的方法和组合物，其中包括胆汁酸转运抑制剂和/或肠内分泌肽增强剂和/或FXR激动剂。